Hasil Pencarian - Martin Wermke

Perbaiki Hasil
  1. 1
    Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide

    Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic triox... oleh Friedrich Stölzel, Martin Wermke, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Martin Bornhäuser

    Diterbitkan 2010-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab

    Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab oleh Martin Wermke, Malte von Bonin, Siegmund Gehrisch, Gabriele Siegert, Gerhard Ehninger, Uwe Platzbecker

    Diterbitkan 2010-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.

    In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. oleh Malte von Bonin, Martin Wermke, Kadriye Nehir Cosgun, Christian Thiede, Martin Bornhauser, Gerard Wagemaker, Claudia Waskow

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

    Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse oleh Katja Sockel, Martin Wermke, Jörgen Radke, Alexander Kiani, Markus Schaich, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede, Uwe Platzbecker

    Diterbitkan 2011-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential Regulator

    Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential Regulator oleh Ceren Güneş, Maciej Paszkowski-Rogacz, Susann Rahmig, Shahryar Khattak, Aylin Camgöz, Martin Wermke, Andreas Dahl, Martin Bornhäuser, Claudia Waskow, Frank Buchholz

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

    Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of thr... oleh Uwe Platzbecker, Joerg Chromik, Jan Krönke, Hiroshi Handa, Stephen Strickland, Yasushi Miyazaki, Martin Wermke, Wataru Sakamoto, Yoshifumi Tachibana, Tillmann Taube, Ulrich Germing

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

    A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome oleh Rami S. Komrokji, Hetty E. Carraway, Ulrich Germing, Martin Wermke, Amer M. Zeidan, Eric Fu, Björn Rüter, Ute Burkard, Annika Osswald, James M. Foran

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

    316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A oleh Aurélien Marabelle, Martin Wermke, Aude de Gassart, Daniel Olive, Patrick Brune, Emmanuel Valentin, Paul Frohna, Christiane Jungels, Norbert Vey, Elena Garralda, Marina Iché

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia

    Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia oleh Uwe Platzbecker, Katja Sockel, Claudia Schönefeldt, Daniel Nowak, Susann Helas, Christoph Röllig, Maximilian Mossner, Johann Christoph Jann, Gerhard Ehninger, Wolf-Karsten Hofmann, Martin Bornhäuser, Christian Thiede, Martin Wermke

    Diterbitkan 2014-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

    Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial oleh Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebreck, Vijay Kasturi, Vikram Chand, James L. Gulley

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation

    In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation oleh Genqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, Uta E. Höpken, Yuntian Ding, David Sedloev, Lei Wang, Avinoam Reichman, Franziska Eberhardt, Martin Wermke, Armin Rehm, Carsten Müller-Tidow, Anita Schmitt, Michael Schmitt

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)

    715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study) oleh Stephane Champiat, Francois-Xavier Danlos, Volker Kunzmann, Martin Wermke, Aude de Gassart, Daniel Olive, Patrick Brune, Emmanuel Valentin, Johann De Bono, Paul Frohna, Marina Iché, Maelle Mairesse, Celine Leparquier, Katrien Lemmens

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

    Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and d... oleh Katja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, Rudolf Trenschel, Martin Wermke, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Jochen Greiner, Dietrich Beelen, Christian Thiede, Gerhard Ehninger, Uwe Platzbecker

    Diterbitkan 2012-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial)

    499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial) oleh Fiona Thistlethwaite, Sylvie Rottey, Emiliano Calvo, Antonia Busse, Martin Wermke, Ralf Wolter, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo, Ioannis Gavvovidis, Marie-Luise Goebeler, Nuria Kotecki, Carolina Perdomo-Ortiz

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

    Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells oleh Avinoam Reichman, Alexander Kunz, Jara J. Joedicke, Uta E. Höpken, Anna Keib, Brigitte Neuber, David Sedloev, Lei Wang, Genqiao Jiang, Angela Hückelhoven-Krauss, Franziska Eberhardt, Carsten Müller-Tidow, Martin Wermke, Armin Rehm, Michael Schmitt, Anita Schmitt

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model

    Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model oleh Elham Pishali Bejestani, Marc Cartellieri, Ralf Bergmann, Armin Ehninger, Simon Loff, Michael Kramer, Johannes Spehr, Antje Dietrich, Anja Feldmann, Susann Albert, Martin Wermke, Michael Baumann, Mechthild Krause, Martin Bornhäuser, Gerhard Ehninger, Michael Bachmann, Malte von Bonin

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease

    Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease oleh Thomas Krüger, Thomas Krüger, Rebekka Wehner, Rebekka Wehner, Rebekka Wehner, Maik Herbig, Maik Herbig, Maik Herbig, Martin Kräter, Martin Kräter, Michael Kramer, Jan Moritz Middeke, Friedrich Stölzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlägel, Martin Wermke, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Jöhrens, Torsten Tonn, Torsten Tonn, Julien Subburayalu, Julien Subburayalu, Julien Subburayalu, Julien Subburayalu, Marc Schmitz, Marc Schmitz, Marc Schmitz, Marc Schmitz, Martin Bornhauser, Martin Bornhauser, Martin Bornhauser, Martin Bornhauser, Malte von Bonin, Malte von Bonin

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study

    776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study oleh James Larkin, Harriet Kluger, Omid Hamid, Jeffrey Weber, Amod A Sarnaik, Brian Gastman, Jeffrey Chou, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Xiao Wu, Jason A Chesney, Giri Sulur, Friedrich Graf Finckenstein

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

    959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA2... oleh Harpreet Singh, Jason Luke, Mamta Kalra, Martin Wermke, Dejka Araujo, Ali Mohamed, Winfried Alsdorf, Apostolia-Maria Tsimberidou, Andrea Mayer-Mokler, Arun Satelli, Carsten Reinhardt, Dominik Maurer, George Jr Blumenschein, Kerstin Guenther, Manik Chatterjee, Norbert Hilf, Regina Mendrzyk, Steffen Walter, Stephen Eck, Tobias AW Holderried, Toni Weinschenk, Van Morris, Cedrik M Britten

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... oleh Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Karl D Lewis, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: